European Commission decision anticipated in JulyBOSTON, May 21, 2021 (GLOBE NEWSWIRE) Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming
BOSTON, May 05, 2021 (GLOBE NEWSWIRE) Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the treatment paradigm for people living with
Rhythm Pharmaceuticals Reports First Quarter 2021 Financial Results
May 03, 2021 08:00 ET | Source: Rhythm Pharmaceuticals, Inc. Rhythm Pharmaceuticals, Inc. First U.S. commercial sales of IMCIVREE™ (setmelanotide) completed late in first quarter – Late-breaking data presentations at ENDO 2021 demonstrated continued weight loss with setmelanotide at up to nine months in HET obesity, as well as weight loss data in adults and BMI-Z reductions in adolescents with Bardet-Biedl syndrome Delivered proof-of-concept data from Phase 2 Basket Study in HET POMC, PCSK1 or LEPR deficiencies, and obesity due to SRC1 and SH2B1 deficiencies Closed $172.5 million public offering and sold Priority Review Voucher for $100 million, providing additional funding to advance continued development of setmelanotide
Rhythm Pharmaceuticals, Inc.: Rhythm Pharmaceuticals to Present at 20th Annual Needham Virtual Healthcare Conference
BOSTON, April 07, 2021 (GLOBE NEWSWIRE) Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced that David Meeker, M.D., Chair, President and Chief Executive Officer, will participate in a fireside chat at the 20
th Annual Needham & Co. Virtual Healthcare Conference on Wednesday, April 14, 2021 at 11:45 a.m. ET.
A live audio webcast of the presentation will be available under Events & Presentations in the Investor Relations section of the Company s website at www.rhythmtx.com. A replay of the webcast will be available on the Rhythm website for 30 days following each presentation.
News Category Global Banking & Finance Reviews
Rhythm Pharmaceuticals Announces Appointments of Camille L. Bedrosian, M.D., and Lynn Tetrault, J.D., to its Board of Directors
Rhythm Pharmaceuticals Announces Appointments of Camille L. Bedrosian, M.D., and Lynn Tetrault, J.D., to its Board of Directors
BOSTON, Dec. 11, 2020 Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced the appointments of Camille L. Bedrosian, M.D., and Lynn Tetrault, J.D., to its Board of Directors.
“I am thrilled to welcome both Camille and Lynn to our Board of Directors, as both leaders have tremendous experience building and leading teams that work effectively to bring new medicines to patients in need,” said David Meeker, M.D., Chair, President and Chief Executive Officer of Rhythm.